Skip to main content
Top
Literature
1.
go back to reference Gale AJ, Pellequer JL (2003) An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 1:1966CrossRefPubMed Gale AJ, Pellequer JL (2003) An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 1:1966CrossRefPubMed
2.
go back to reference Gale AJ, Radtke KP, Cunningham MA et al (2006) Intrinsic stability, functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 4:1315CrossRefPubMed Gale AJ, Radtke KP, Cunningham MA et al (2006) Intrinsic stability, functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 4:1315CrossRefPubMed
3.
go back to reference Sarafanov AG, Ananyeva NM, Shima M et al (2001) Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 276:11970CrossRefPubMed Sarafanov AG, Ananyeva NM, Shima M et al (2001) Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 276:11970CrossRefPubMed
4.
go back to reference Miao HZ, Sirachainan N, Palmer L et al (2004) Bioengineering of coagulation factor VIII for improved secretion. Blood 103:3412CrossRefPubMed Miao HZ, Sirachainan N, Palmer L et al (2004) Bioengineering of coagulation factor VIII for improved secretion. Blood 103:3412CrossRefPubMed
5.
go back to reference Swaroop M, Moussalli M, Pipe SW et al (1997) Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem 272:24121CrossRefPubMed Swaroop M, Moussalli M, Pipe SW et al (1997) Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem 272:24121CrossRefPubMed
6.
go back to reference Begbie M, Notley C, Tinlin S et al (2000) The Factor VIII acute phase response requires the participation of NFkappaB, C/EBP. Thromb Haemost 84:216PubMed Begbie M, Notley C, Tinlin S et al (2000) The Factor VIII acute phase response requires the participation of NFkappaB, C/EBP. Thromb Haemost 84:216PubMed
Metadata
Title
“Novel strategies to Improve Recombinant Factor VIII Production and its in vivo Recovery”
Author
Raghuveer Prabhu
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2010
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-010-0036-0

Other articles of this Issue 3/2010

Indian Journal of Hematology and Blood Transfusion 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine